Predictors and Impact of Thirty-Day Readmission on Patient Outcomes and Health Care Costs after Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation
Sherri Rauenzahn(West Virginia University), Abraham S. Kanate(HonorHealth), Londia Goff(West Virginia University), Sijin Wen(The University of Texas MD Anderson Cancer Center), Sonia Leadmon(West Virginia University), Kim Evans(Baylor College of Medicine), Michael Craig(Edith Cowan University), Jianjun Zhang(The University of Texas MD Anderson Cancer Center), Aaron Cumpston(West Virginia University Hospitals), Quoc Truong(West Virginia University), Mehdi Hamadani(Medical College of Wisconsin)
Cited by 18
Related Papers
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
|The Lancet Oncology|2016|1.1k
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
|Proceedings of the National Academy of Sciences|2007|517